P750 Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitis

Abstract

Cyclosporin A is a second-line drug in ulcerative colitis that failed to respond to intravenous glucocorticoids according to ECCO/ESPGHAN consensus . Up-to-date CsA induced mucosal healing (Mayo 0 score) is the only factor predicting the lack of course deterioration in the future. The aim of the study was to investigate a presence of factors contributing to positive CsA therapy outcome. It is a retrospective, single center study. We describe a clinical characteristic of 59 children (33 females, 26 males), mean age of 13.7 years, mean disease duration 32 months, who underwent CsA treatment in the course of UC in years 2005–2015. The primary endpoint was clinical remission (defined as PUCAI<10) or clinical response (defined as decrease in PUCAI scoring for at least 20 points) at Day 8. Response/remission at Day 8 was achieved in 43 out of 59 (81%) and 31 out of 59 (58%) patients, respectively. Clinical (PUCAI score), laboratory (CsA concentration), endoscopic (disease extension and severity) and demographic (age, age of onset, disease duration) data were used as independent variables in analysis of discrimination between: group with clinical response vs. no response and group with clinical remission vs. no remission. PUCAI score, UC duration and Mayo score create the model which predict clinical remission at Day 8 with sensitivity 0.8 and specificity 0.66. No model was established to discriminate between groups with clinical response vs. no response. PUCAI score, UC duration and Mayo score contribute to response for induction therapy with CsA in children with UC.